The lines worth reading twice from today’s edition. Full issue linked at the bottom.
1. LIC’s profit rose 23%, its margin rose more
LIC’s Q1 net profit climbed 22.8% to Rs 13,492 crore, but premium income grew a far calmer 6.75%. The gap is the story. The value of new business margin, the profit locked into each fresh policy, jumped 750 basis points to 22.9%. LIC is finally selling more protection cover and fewer thin savings plans, narrowing a margin gap private insurers held for two decades. The open question is whether richer margins quietly come with slower volume, since Indians still buy far less pure protection than savings. (Business Standard)
2. Godrej sold more, kept less per rupee
Godrej Consumer’s June-quarter revenue grew in the high teens, near 17%, on high-single-digit volume growth across home and personal care. Margins went the other way: gross margin narrowed about 80 basis points to roughly 51% as crude and palm-derived input costs climbed and sourcing gaps dented fill rates. So the shopper bought more soap, insecticide and hair colour while the maker earned slightly less on each unit. It is the signature of this FMCG season, volumes recovering, margins pinched, with Indonesia still a drag on the group number. (Business Standard)
3. BPCL earned record refining margins, lost money selling fuel
BPCL slipped to a consolidated net loss of Rs 1,872 crore for the June quarter, against a Rs 6,839 crore profit a year earlier, even as its refining margin hit 41.4 dollars a barrel, more than eight times the year-ago level. The loss came from selling petrol, diesel and cooking gas at capped prices while crude spiked and the rupee weakened, turning the marketing margin negative. State refiners carry a hidden trade: when crude rises, pump prices stay put, and they absorb the cost of stable fuel inflation. HPCL reported the same squeeze. (Business Standard)
4. Molbio’s IPO bets on the village lab
Molbio Diagnostics set a price band of Rs 768 to 807 for a roughly Rs 940 crore IPO opening August 10, with the anchor book on August 7 and listing tentatively August 17. Molbio does not run lab chains. It makes Truenat, a portable device that runs molecular tests for tuberculosis and other diseases at a health centre instead of a city lab. India’s diagnostics money has mostly chased urban lab networks. This is a bet on the box that moves the test to where the patient already is, expanding the addressable population rather than fighting over the metro one. (Business Today)
5. India’s services cooled at home, leaned abroad
The HSBC India Services PMI fell to 53.3 in July from 57.4 in June, still growth but the slowest in more than four years. Firms blamed softer domestic demand, more competition and fewer new enquiries. One line pulled the other way: new export orders grew faster than overall new business, with stronger demand from clients in the UAE, the UK and the US, and hiring picked up again. Services are the larger half of India’s economy, so a domestic customer pausing while the overseas one does not quietly shifts where the growth is coming from. (HSBC / Business Standard)
Read today’s full edition, with two more stories and a 30-second scan, here: https://theinsightlabs.in/daily/2026-08-07
Reply and tell me which line landed. I read every response.
— Satyam · The Insight Labs